The National Development and Reform Commission added 442 million yuan to support the biopharmaceutical industry, and the prospect of biopharmaceutical specialty is promising. A major breakthrough in biotechnology is rapidly gestating and giving birth to a new industrial revolution, and the biological industry will become another new leading industry in the world economy after the information industry. In recent years, governments at all levels, from national to local, have continuously increased their support for the development of biomedical industry.

From June to July, 2007, the total industrial output value of China's bio-biochemical products manufacturing industry reached 47,703,454,000 yuan, up 19.92% year-on-year. From June to August 2008, the overall economy of biopharmaceutical industry still maintained a growth trend. From June 5438 to August 2008, China's bio-chemical products manufacturing industry achieved a total industrial output value of 49,240.86 million yuan, a year-on-year increase of 30.34%. Accumulated product sales revenue was 44,620.73 million yuan, up 30.32% year-on-year; The accumulated total profit was 5,665,679,000 yuan, a year-on-year increase of 40.37%. In the shadow of the global financial crisis, the pharmaceutical market in emerging countries stands out. As one of the BRIC countries, China's biopharmaceutical market is particularly bright. The National Development and Reform Commission allocated an additional 442 million yuan from the central government to support special projects such as high-tech industrialization of biomedicine, biological breeding and biomedical engineering, and the construction of public service conditions in the national bio-industrial base. This move has injected new impetus into the future development of biopharmaceuticals.

Generally speaking, the future of biopharmaceutical industry in China is full of hope and promising. Looking ahead, the biopharmaceutical industry in China will continue to grow. In the future, China's biological and biochemical products industry will still show a rapid development trend.

During the Eleventh Five-Year Plan period, China will vigorously develop high-tech industries, among which biopharmaceuticals, as one of the five major industries, show a good development momentum. This is an opportunity for biopharmaceutical specialty, which has formulated a set of talent training policies with its own characteristics according to the market demand for talents and social demand. With the support of policies, schools and society, biopharmaceutical specialty will show more attractive prospects.